

Caroline M Tanner

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4203544/caroline-m-tanner-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96
papers

10,446
citations

42
h-index

102
g-index

104
ext. papers

13,254
ext. citations

8.5
avg, IF

6.08
L-index

#	Paper	IF	Citations
96	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17013	51.1	1700
95	Incidence of Parkinson disease: variation by age, gender, and race/ethnicity. <i>American Journal of Epidemiology</i> , 2003 , 157, 1015-22	3.8	980
94	Rotenone, paraquat, and Parkinson disease. <i>Environmental Health Perspectives</i> , 2011 , 119, 866-72	8.4	804
93	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , 2011 , 95, 629-35	10.9	793
92	Parkinson disease in twins: an etiologic study. <i>JAMA - Journal of the American Medical Association</i> , 1999 , 281, 341-6	27.4	594
91	Association of olfactory dysfunction with risk for future Parkinson disease. <i>Annals of Neurology</i> , 2008 , 63, 167-73	9.4	525
90	Epidemiology of Parkinson disease. <i>Neurologic Clinics</i> , 1996 , 14, 317-35	4.5	413
89	Urate as a predictor of the rate of clinical decline in Parkinson disease. <i>Archives of Neurology</i> , 2009 , 66, 1460-8		265
88	Association of cerebrospinal fluid A β 1-42, T-tau, P-tau181, and Synuclein levels with clinical features of drug-naïve patients with early Parkinson disease. <i>JAMA Neurology</i> , 2013 , 70, 1277-87	17.2	252
87	The role of environmental toxins in the etiology of Parkinson disease. <i>Trends in Neurosciences</i> , 1989 , 12, 49-54	13.3	236
86	Head injury and Parkinson disease risk in twins. <i>Annals of Neurology</i> , 2006 , 60, 65-72	9.4	191
85	Traumatic brain injury in later life increases risk for Parkinson disease. <i>Annals of Neurology</i> , 2015 , 77, 987-95	9.4	175
84	Natural history of multiple system atrophy in the USA: a prospective cohort study. <i>Lancet Neurology</i> , 2015 , 14, 710-9	24.1	169
83	Occupation and risk of parkinsonism: a multicenter case-control study. <i>Archives of Neurology</i> , 2009 , 66, 1106-13		160
82	Association of olfactory dysfunction with incidental Lewy bodies. <i>Movement Disorders</i> , 2006 , 21, 2062-7	7	156
81	Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 584-93	27.4	153
80	Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. <i>Clinics in Geriatric Medicine</i> , 2020 , 36, 1-12	3.8	143

79	The Parkinson [®] progression markers initiative (PPMI) - establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1460-1477	5.3	142
78	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2017 , 74, 941-949	17.2	112
77	Biomarker-driven phenotyping in Parkinson [®] disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017 , 32, 319-324	7	111
76	Predictors of deterioration in health-related quality of life in Parkinson [®] disease: results from the DATATOP trial. <i>Movement Disorders</i> , 2008 , 23, 653-9; quiz 776	7	109
75	Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson [®] disease (EASE LID 3). <i>Movement Disorders</i> , 2017 , 32, 1701-1709	7	103
74	Pre-motor features of Parkinson [®] disease: the Honolulu-Asia Aging Study experience. <i>Parkinsonism and Related Disorders</i> , 2012 , 18 Suppl 1, S199-202	3.6	102
73	Prediction of cognition in Parkinson [®] disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , <i>The</i> , 2017 , 16, 620-629	24.1	98
72	Solvent exposures and Parkinson disease risk in twins. <i>Annals of Neurology</i> , 2012 , 71, 776-84	9.4	97
71	Dopamine transporter imaging is associated with long-term outcomes in Parkinson [®] disease. <i>Movement Disorders</i> , 2012 , 27, 1392-7	7	94
70	Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. <i>Archives of Neurology</i> , 2010 , 67, 1116-22		90
69	How stable are Parkinson [®] disease subtypes in de novo patients: Analysis of the PPMI cohort?. <i>Parkinsonism and Related Disorders</i> , 2016 , 28, 62-7	3.6	89
68	Nicotine and Parkinson [®] disease: implications for therapy. <i>Movement Disorders</i> , 2008 , 23, 1641-52	7	88
67	Dietary fat intake, pesticide use, and Parkinson [®] disease. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 82-7	3.6	81
66	Clinical features in early Parkinson disease and survival. <i>Archives of Neurology</i> , 2009 , 66, 1353-8		78
65	Current and projected future economic burden of Parkinson [®] disease in the U.S. <i>Npj Parkinson's Disease</i> , 2020 , 6, 15	9.7	78
64	Longitudinal Change of Clinical and Biological Measures in Early Parkinson [®] Disease: Parkinson [®] Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018 , 33, 771-782	7	73
63	Head injury, β -synuclein Rep1, and Parkinson [®] disease. <i>Annals of Neurology</i> , 2012 , 71, 40-8	9.4	66
62	The best medicine? The influence of physical activity and inactivity on Parkinson [®] disease. <i>Movement Disorders</i> , 2016 , 31, 1444-1454	7	64

61	Advances in environmental epidemiology. <i>Movement Disorders</i> , 2010 , 25 Suppl 1, S58-62	7	60
60	Mendelian randomization of serum urate and parkinson disease progression. <i>Annals of Neurology</i> , 2014 , 76, 862-8	9.4	58
59	The Effect of the COVID-19 Pandemic on People with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1365-1377	5.3	56
58	The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk. <i>Alzheimer's and Dementia</i> , 2014 , 10, S213-25	1.2	55
57	Longitudinal analyses of cerebrospinal fluid β Synuclein in prodromal and early Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 1354-1364	7	48
56	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 102-106	3.6	42
55	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , 2020 , 19, 71-80	24.1	37
54	Concordance for Parkinson's disease in twins: A 20-year update. <i>Annals of Neurology</i> , 2019 , 85, 600-605	9.4	35
53	A specific amino acid motif of mediates risk and interacts with smoking history in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 7419-7424	11.5	33
52	Knowledge gaps and research recommendations for essential tremor. <i>Parkinsonism and Related Disorders</i> , 2016 , 33, 27-35	3.6	33
51	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020 , 35, 1999-2008	7	32
50	National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. <i>Telemedicine Journal and E-Health</i> , 2016 , 22, 590-8	5.9	31
49	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. <i>JAMA Neurology</i> , 2016 , 73, 102-10	17.2	29
48	Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. <i>JAMA Neurology</i> , 2013 , 70, 1382-8	17.2	29
47	Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson's disease. <i>Scientific Data</i> , 2020 , 7, 67	8.2	27
46	β Adrenoreceptors and the risk of Parkinson's disease. <i>Lancet Neurology</i> , 2020 , 19, 247-254	24.1	27
45	Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020 , 35, 1755-1764	7	21
44	Parkinson's disease research in a prospective cohort in China. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1200-4	3.6	19

43	The Impact of COVID-19 on Access to Parkinson's Disease Medication. <i>Movement Disorders</i> , 2020 , 35, 2129-2133	7	19
42	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. <i>Movement Disorders</i> , 2020 , 35, 833-844	7	18
41	Virtual visits for Parkinson disease: A multicenter noncontrolled cohort. <i>Neurology: Clinical Practice</i> , 2017 , 7, 283-295	1.7	18
40	Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. <i>Clinical Neuropharmacology</i> , 2015 , 38, 163-9	1.4	18
39	Caffeine, creatine, GRIN2A and Parkinson's disease progression. <i>Journal of the Neurological Sciences</i> , 2017 , 375, 355-359	3.2	17
38	Parkinson's disease and motor-neuron disease in former prisoners-of-war. <i>Lancet, The</i> , 2000 , 355, 843	4.0	17
37	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> , 2020 , 88, 574-587	9.4	16
36	Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease. <i>Movement Disorders</i> , 2018 , 33, 472-478	7	16
35	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 543-558	5.3	12
34	Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP). <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 553635	5.3	12
33	Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 183-190	2.2	11
32	Cervical dystonia incidence and diagnostic delay in a multiethnic population. <i>Movement Disorders</i> , 2020 , 35, 450-456	7	11
31	Remote smartphone monitoring of Parkinson's disease and individual response to therapy. <i>Nature Biotechnology</i> , 2021 ,	44.5	11
30	Remote telemedicine evaluation of deep brain stimulation candidacy: Retrospective cohort analysis. <i>Neurology: Clinical Practice</i> , 2020 , 10, 199-205	1.7	10
29	Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 677-691	5.3	10
28	A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 620-627	1.7	10
27	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019 , 62, 201-209	3.6	9
26	Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. <i>CNS Spectrums</i> , 2020 , 1-10	1.8	9

25	Electrocardiographic changes predate Parkinson's disease onset. <i>Scientific Reports</i> , 2020 , 10, 11319	4.9	9
24	Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 665-675	5.3	9
23	Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. <i>Journal of Parkinson's Disease</i> , 2019 , 9, 665-679	5.3	8
22	Video-based Parkinson's disease assessments in a nationwide cohort of Fox Insight participants. <i>Clinical Parkinsonism & Related Disorders</i> , 2021 , 4, 100094	0.9	8
21	When brawn benefits brain: physical activity and Parkinson's disease risk. <i>Brain</i> , 2015 , 138, 238-9	11.2	7
20	Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology. <i>Movement Disorders</i> , 2019 , 34, 228-235	7	6
19	Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 308-320	5.3	6
18	Dopamine transporter imaging predicts clinically-defined β -synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 201-212	5.3	6
17	Impaired Cognition and the Risk of Parkinson Disease: Trouble in Mind. <i>JAMA Neurology</i> , 2017 , 74, 1398-1400	14.0	5
16	The Microbiome in Neurodegenerative Disease. <i>Current Geriatrics Reports</i> , 2018 , 7, 81-91	1.3	5
15	The NAS-NRC Twin Registry and Duke Twins Study of Memory in Aging: An Update. <i>Twin Research and Human Genetics</i> , 2019 , 22, 757-760	2.2	4
14	Exploring the clinical burden of OFF periods in Parkinson disease. <i>American Journal of Managed Care</i> , 2020 , 26, S255-S264	2.1	2
13	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. <i>Npj Parkinson's Disease</i> , 2021 , 7, 16	9.7	2
12	Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. <i>Neurology and Therapy</i> , 2021 , 10, 307-320	4.6	2
11	Translation, Validation, Diagnostic Accuracy, and Reliability of Screening Questionnaire for Parkinsonism in Three African Countries. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1113-1122	5.3	1
10	Recruitment for Remote Decentralized Studies in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021 ,	5.3	1
9	Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 1972-1978	7	1
8	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 53-58	2.2	1

7	Occupational exposures and parkinsonism among Shanghai women textile workers. <i>American Journal of Industrial Medicine</i> , 2018 , 61, 886-892	2.7	1
6	The epidemiology of cognitive function in Parkinson's disease.. <i>Progress in Brain Research</i> , 2022 , 269, 3-37	2.9	0
5	Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.. <i>Npj Parkinson's Disease</i> , 2022 , 8, 29	9.7	0
4	Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 245-246	3.6	
3	Reply to: Diagnostic Delay in Cervical Dystonia-Dystonia With Antecedent ET?. <i>Movement Disorders</i> , 2020 , 35, 1086-1087	7	
2	Bad Air and Parkinson Disease-The Fog May Be Lifting. <i>JAMA Neurology</i> , 2021 , 78, 793-795	17.2	
1	Enhancing Clinical Information Display to Improve Patient Encounters: Human-Centered Design and Evaluation of the Parkinson Disease-BRIDGE Platform.. <i>JMIR Human Factors</i> , 2022 , 9, e33967	2.5	